Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Effect of concurrent TP53 mutation in EGFR/ALK/ROS1 positive non-small cell lung cancer treated with first-line TKI therapy: A Single Institution Retrospective Study.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20592

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20592)

Author(s): Sandhya Sharma, Emily Miao, Joanna Stein Fishbein, Chung-Shien Lee, Kevin M. Sullivan, Nagashree Seetharamu; Monter Cancer Center at Northwell Health, Lake Success, NY; St. John's University, Great Neck, NY; Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY; Monter Cancer Center-Northwell Health, Lake Success, NY; Monter Cancer Center at Northwell Health, New York, NY

Abstract Disclosures

Abstract:

Background: Tyrosine Kinase Inhibitors (TKI) are the mainstay of therapy for patients (pts) with EGFR/ALK/ROS1 positive (pos) non-small cell lung cancer (NSCLC), however resistance to these drugs is inevitable and remains a clinical challenge. The cause for early resistance leading to progression has not been fully understood, but several mechanisms have been reported. We conducted a retrospective study to determine the impact of concurrent TP53 mutation (TP53m) in this population. Methods: NSCLC pts treated with first line TKI from 01/2014 to 06/2017 were studied. Descriptive statistics were computed. Progression was equated with TKI resistance (TKIr). We compared time to TKIr among pts with TP53m to those without. Standard survival analysis methods (i.e., Kaplan-Meier curves and multivariable Cox proportional hazards regression) were used. Results: Forty-two subjects on first line treatment TKI were included. The mean (SD) age was 67.2 (14.7) years. 37 (88%) were EGFR, 4 (10%) were ALK and 1 (2%) were ROS pos. 76% were female, 50% White, 74% non-smokers and 50% had a TP53m. The estimated median time to TKIr was 19.4 months. At 24 months from start of therapy, the predicted probability of not reaching TKIr was 46% (95% CI: 26-64%). The estimated median time to TKIr among those without TP53m is 19.4 months vs 14.4 months in those with TP53m (p = 0.13). The predicted probability of no TKIr at 12 months from start of therapy among those with and without TP53m were 59% and 80%, respectively. In multivariable analysis, TP53 status remained nonsignificant (p = 0.08) after adjusting for line of therapy. Conclusions: TP53m has been associated with worse prognosis in various cancers. The results from the studies looking at association between TP53m and NSCLC with targetable mutation have been mixed, with few studies demonstrating the association of TP53m with poor survival and earlier treatment resistance. In our study, although there was a tendency towards improved survival and delayed TKIr in the cohort without TP53m, it was not statistically significant, which may be due to small sample size. Further studies looking at concurrent TP53m and targetable mutation are required, which may help clinicians deciding how to direct therapy in this population.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...